FDA Classifies Antibiotic Bone Void Fillers as Class II

The Lesson Before the Rule

Here's the strategic lesson before we get into the regulation itself: a single company's De Novo request, filed four years ago for one product, just became the classification regulation every future competitor has to build against. If you're developing a combination product with no existing product code to slot into, the De Novo pathway isn't just a way to get your own device to market — it's an opportunity to write the special controls the whole product category will live under. BONESUPPORT AB didn't just get CERAMENT G classified; it shaped 21 CFR 888.3046 for everyone who comes after. Now here's what actually changed.

What FDA Actually Changed on June 5, 2026

On June 5, 2026, FDA published a final order in the Federal Register — Docket No. FDA-2026-N-5195, 91 FR 34148 — classifying "the resorbable calcium salt bone void filler containing a single approved aminoglycoside antibacterial" into Class II with special controls. The order is effective as of its publication date, June 5, 2026. There's no comment period attached to it, because this is a final order implementing a De Novo classification already granted, not a proposed rule inviting public input.

The New Regulation: 21 CFR 888.3046

The order adds a new section to Part 888 (Orthopedic Devices), Subpart D: 21 CFR 888.3046. If you work in orthopedic or combination-product regulatory affairs, this is the citation you now cite. The regulation defines the device as a resorbable implant intended to fill bony defects of the extremities where there's an increased risk of infection, intended to resorb over time and be replaced by new bone, for reducing the recurrence of chronic osteomyelitis of long bones. FDA is explicit on one point that matters for labeling and claims: the product is not intended to treat infection. That distinction — reducing recurrence risk versus treating an active infection — runs through every special control in the order.

Where This Product Came From: BONESUPPORT AB's De Novo Request

FDA received BONESUPPORT AB's De Novo request for CERAMENT G on September 28, 2021. Under section 513(f)(2) of the FD&C Act (21 U.S.C. 360c(f)(2)), FDA had 120 days to issue a written classification order once the request was properly before it, and issued that order to the requester on May 17, 2022, classifying the product into Class II. What happened between May 2022 and June 2026 is itself instructive: FDA granted the individual company's request in 2022, then took roughly four years to codify the generic classification in the CFR so the special controls would apply to everyone, not just the original requester. If you're the first mover with a De Novo grant, don't assume the codified regulation lands the same week your own clearance does. There's a real gap, and during that gap you're operating under the terms of your own De Novo order while the rest of the industry waits for the published rule.

Without this action, any device not in commercial distribution before May 28, 1976 is automatically classified into Class III by operation of law under 21 U.S.C. 360c(f)(1) — regardless of actual risk — and requires premarket approval. FDA calls these "postamendments devices." The De Novo pathway exists specifically to pull a novel, lower-risk device out of that automatic Class III bucket without forcing a PMA.

Before and After: Class III to Class II

That last row matters more than it looks. Class II status usually raises the question of whether FDA will exempt the device type from 510(k) entirely under section 510(m) of the FD&C Act. FDA addressed this directly in the order: it has not made that determination for resorbable calcium salt bone void fillers containing a single approved aminoglycoside antibacterial. Every future entrant still files a premarket notification.

The 15 Special Controls, and Why FDA Wrote Them This Way

FDA didn't write generic special controls here. It wrote them against a specific risk table, and the table is worth reading closely because it tells you exactly what a reviewer will ask for. FDA identified eight categories of risk to health for this product type: recurring, persistent, or new infection; adverse tissue reaction; antimicrobial resistance; transient electrolyte imbalance (hyperkalemia, hypercalcemia, or hypocalcemia); incomplete or lack of bone formation; pathologic fracture; product migration or extrusion; and drug-induced toxicity such as nephrotoxicity and ototoxicity.

Against those eight risks, the order codifies fifteen special controls under 21 CFR 888.3046(b)(1) through (15):

1. Clinical performance testing, including safe aminoglycoside serum levels below toxic concentrations
2. Animal performance testing in a large-animal osteomyelitis infection model
3. Non-clinical elution kinetics and dissolution testing
4. Drug substance and drug constituent part characterization against USP monographs
5. Antimicrobial resistance analysis
6. Susceptibility testing on bacterial isolates from clinical testing
7. Conditional postmarket surveillance if clinical data is insufficient to evaluate long-term safety
8. Biocompatibility of the product and its delivery components
9. Container closure compatibility
10. Sterility and pyrogenicity performance data
11. Expiration dating and shelf-life data
12. Stability testing across three long-term and accelerated-stability batches
13. Pharmaceutical manufacturing information, including CGMP compliance under 21 CFR part 211 or the combination-product subset in 21 CFR part 4, subpart A
14. A hard requirement that the product contain a single approved aminoglycoside antibacterial
15. A detailed labeling package covering maximum implant volume, technical parameters, adverse events, antimicrobial resistance warnings, and precautions against overfilling, overpressuring, and disturbing the product before it sets

Notice how many of those controls are drug-side, not device-side. This is a combination product in substance even where it's regulated as a device, and the special controls read like it: drug master file references, USP compendial testing, elution profiles, degradation products. If your quality team has only ever built device design history files, this classification is a signal to bring pharmaceutical quality expertise into the room early.

What This Means If You're Building a Combination Product

You Can Now Use a 510(k), Not a PMA — But You Still Need One

If you're developing a competing resorbable, antibiotic-eluting bone void filler for long-bone osteomyelitis recurrence, you no longer face the automatic Class III/PMA default. You can pursue a 510(k) under 21 CFR part 807, subpart E, using either CERAMENT G or a subsequently cleared device as your predicate, and you build your submission around the fifteen controls in 888.3046(b) rather than a full PMA dossier. That's a meaningfully lower regulatory bar in terms of pathway, but it isn't a lighter evidentiary bar — the clinical, animal, and non-clinical testing requirements written into the special controls are extensive. I've walked clients through what an FDA 510(k) submission actually demands in our guide to the process, and this classification is a clean example of how special controls can functionally require PMA-grade data while keeping you on the 510(k) track procedurally.

Build Your Design History File Around the Risk Table

FDA's Table 1 in the order — the risk-to-mitigation mapping — is effectively a pre-built risk management file outline. Each of the eight identified risks maps to specific mitigation measures FDA already expects to see. If your design controls process under 21 CFR 820.30 doesn't produce documentation that traces cleanly to each of those eight risks, you have a gap before you've even drafted a 510(k). This is exactly the kind of risk-to-control traceability that a properly integrated ISO 14971 risk management file is built to produce, and it's worth reading through how ISO 14971 integrates with your broader ISO 13485 QMS if your risk file isn't already structured this way.

Practical Compliance Checklist

• Confirm your product's aminoglycoside is FDA-approved and that your formulation contains a single approved aminoglycoside — 888.3046(b)(14) makes this a hard requirement, not a preference.
• Map your clinical protocol to demonstrate serum aminoglycoside levels stay below toxic concentrations, not just efficacy against recurrence.
• Plan for a large-animal osteomyelitis infection model in your non-clinical program — a small-animal or in vitro-only package will not satisfy 888.3046(b)(2).
• Line up drug master file access or direct characterization data for the drug substance; USP monograph conformance is explicitly required under 888.3046(b)(4)(ii).
• Confirm your CGMP compliance approach — full 21 CFR part 211, or the combination-product subset under 21 CFR part 4, subpart A — and document which one applies to each manufacturing site.
• Build your labeling draft against all seven sub-elements of 888.3046(b)(15) before you finalize instructions for use, including the antimicrobial resistance warning and the precautions against overfilling, overpressuring, and disturbing the product before it sets.
• Ask FDA directly during pre-submission whether it will require postmarket surveillance under 888.3046(b)(7) for your specific clinical dataset — the order makes PMS conditional, not automatic.

Effective Dates and Deadlines at a Glance

There's no compliance grace period here in the sense of a recall or a warning letter response deadline — this is a classification regulation, not an enforcement action. But the dates still matter for anyone submitting now.

If you file a 510(k) for this device type today, you're submitting against a codified regulation, not an informal De Novo precedent. That's a stronger footing procedurally, but it also means FDA reviewers now have a checklist with your name on every line item.

How This Connects to Your ISO 13485 QMS

Special controls don't replace your quality management system — they tell you what your QMS has to be able to prove. Every one of the fifteen controls in 888.3046(b) needs a corresponding procedure, record, and verification activity somewhere in your ISO 13485-conformant QMS: design controls for the clinical and animal testing protocols, purchasing and supplier controls for the drug substance and DMF relationships, process validation for sterilization and the in situ setting characteristics, and document control for the labeling package. In my experience, the companies that struggle with a classification like this aren't the ones with weak science — they're the ones whose QMS wasn't built to hold pharmaceutical-grade documentation alongside device-grade documentation. If you're building or auditing that structure, I've written more broadly about what a compliant risk management approach looks like under ISO 14971, which is the natural home for the risk-to-control mapping this order requires.

Frequently Asked Questions

What is 21 CFR 888.3046 and when did it take effect? 21 CFR 888.3046 is the new FDA regulation classifying the resorbable calcium salt bone void filler containing a single approved aminoglycoside antibacterial into Class II with special controls. It was added to Part 888, Subpart D by a final order published June 5, 2026 (91 FR 34148, Docket No. FDA-2026-N-5195), effective the same day.

Does this classification exempt the product from premarket notification? No. FDA explicitly stated in the final order that it has not made a 510(k) exemption determination under section 510(m) of the FD&C Act for this product type. Every manufacturer, including future entrants, must still submit a premarket notification under 21 CFR part 807, subpart E.

What product triggered this classification? BONESUPPORT AB's De Novo request for CERAMENT G, submitted September 28, 2021. FDA granted the original De Novo classification to the requester on May 17, 2022; the June 2026 order codifies that classification as a generic regulation applicable to the whole product type.

Can a competitor now use CERAMENT G as a 510(k) predicate? Yes. Under section 513(f)(2)(B)(i) of the FD&C Act, a device classified through De Novo can serve as a predicate for future 510(k) submissions of substantially equivalent devices, which is one of the stated reasons FDA gives for using the De Novo pathway — it lets later entrants use the "less burdensome" 510(k) process instead of filing their own De Novo request.

Why does this classification include drug-manufacturing controls if it's a device regulation? Because the product is a device/drug combination in substance — a resorbable implant that elutes an approved aminoglycoside antibacterial. The special controls in 888.3046(b) require drug substance characterization against USP monographs, CGMP documentation under 21 CFR part 211 or the combination-product subset in 21 CFR part 4, subpart A, and elution/stability testing typical of a drug product, layered on top of standard device performance and biocompatibility requirements.

Last updated: 2026-08-26